| Segment and Geographic Area Information |
Segment and Geographic Area Information AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie's net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | years ended December 31 (in millions) | 2019 | | 2018 | | 2017 | Immunology | | | | | | HUMIRA | United States | $ | 14,864 |
| | $ | 13,685 |
| | $ | 12,361 |
| | International | 4,305 |
| | 6,251 |
| | 6,066 |
| | Total | $ | 19,169 |
| | $ | 19,936 |
| | $ | 18,427 |
| SKYRIZI | United States | $ | 311 |
| | $ | — |
| | $ | — |
| | International | 44 |
| | — |
| | — |
| | Total | $ | 355 |
| | $ | — |
| | $ | — |
| RINVOQ | United States | $ | 47 |
| | $ | — |
| | $ | — |
| | International | — |
| | — |
| | — |
| | Total | $ | 47 |
| | $ | — |
| | $ | — |
| Hematologic Oncology | | | | | | IMBRUVICA | United States | $ | 3,830 |
| | $ | 2,968 |
| | $ | 2,144 |
| | Collaboration revenues | 844 |
| | 622 |
| | 429 |
| | Total | $ | 4,674 |
| | $ | 3,590 |
| | $ | 2,573 |
| VENCLEXTA | United States | $ | 521 |
| | $ | 247 |
| | $ | 89 |
| | International | 271 |
| | 97 |
| | 33 |
| | Total | $ | 792 |
| | $ | 344 |
| | $ | 122 |
| HCV | | | | | | MAVYRET | United States | $ | 1,473 |
| | $ | 1,614 |
| | $ | 277 |
| | International | 1,420 |
| | 1,824 |
| | 213 |
| | Total | $ | 2,893 |
| | $ | 3,438 |
| | $ | 490 |
| VIEKIRA | United States | $ | — |
| | $ | 3 |
| | $ | 61 |
| | International | 36 |
| | 175 |
| | 723 |
| | Total | $ | 36 |
| | $ | 178 |
| | $ | 784 |
| Other Key Products | | | | | | Creon | United States | $ | 1,041 |
| | $ | 928 |
| | $ | 831 |
| Lupron | United States | $ | 720 |
| | $ | 726 |
| | $ | 669 |
| | International | 167 |
| | 166 |
| | 160 |
| | Total | $ | 887 |
| | $ | 892 |
| | $ | 829 |
| Synthroid | United States | $ | 786 |
| | $ | 776 |
| | $ | 781 |
| Synagis | International | $ | 718 |
| | $ | 726 |
| | $ | 738 |
| Duodopa | United States | $ | 97 |
| | $ | 80 |
| | $ | 61 |
| | International | 364 |
| | 350 |
| | 294 |
| | Total | $ | 461 |
| | $ | 430 |
| | $ | 355 |
| Sevoflurane | United States | $ | 74 |
| | $ | 74 |
| | $ | 78 |
| | International | 274 |
| | 317 |
| | 332 |
| | Total | $ | 348 |
| | $ | 391 |
| | $ | 410 |
| Kaletra | United States | $ | 38 |
| | $ | 55 |
| | $ | 71 |
| | International | 245 |
| | 281 |
| | 352 |
| | Total | $ | 283 |
| | $ | 336 |
| | $ | 423 |
| AndroGel | United States | $ | 172 |
| | $ | 469 |
| | $ | 577 |
| ORILISSA | United States | $ | 91 |
| | $ | 11 |
| | $ | — |
| | International | 2 |
| | — |
| | — |
| | Total | $ | 93 |
| | $ | 11 |
| | $ | — |
| All other | | $ | 511 |
| | $ | 308 |
| | $ | 876 |
| Total net revenues | $ | 33,266 |
| | $ | 32,753 |
| | $ | 28,216 |
|
Net revenues to external customers by geographic area, based on product shipment destination, were as follows: | | | | | | | | | | | | | years ended December 31 (in millions) | 2019 | | 2018 | | 2017 | United States | $ | 23,907 |
| | $ | 21,524 |
| | $ | 18,251 |
| Japan | 1,211 |
| | 1,591 |
| | 764 |
| Germany | 909 |
| | 1,292 |
| | 1,157 |
| Canada | 813 |
| | 730 |
| | 659 |
| France | 695 |
| | 783 |
| | 730 |
| Spain | 472 |
| | 611 |
| | 521 |
| United Kingdom | 372 |
| | 855 |
| | 807 |
| Italy | 372 |
| | 652 |
| | 475 |
| Brazil | 359 |
| | 350 |
| | 410 |
| The Netherlands | 163 |
| | 352 |
| | 362 |
| All other countries | 3,993 |
| | 4,013 |
| | 4,080 |
| Total net revenues | $ | 33,266 |
| | $ | 32,753 |
| | $ | 28,216 |
|
Long-lived assets, primarily net property and equipment, by geographic area were as follows: | | | | | | | | | as of December 31 (in millions) | 2019 | | 2018 | United States and Puerto Rico | $ | 2,026 |
| | $ | 1,993 |
| Europe | 646 |
| | 599 |
| All other | 290 |
|
| 291 |
| Total long-lived assets | $ | 2,962 |
| | $ | 2,883 |
|
|